CODX - Incyte's Approval And Other News: The Good Bad And Ugly Of Biopharma
Incyte Receives the FDA Approval for Pemazyre
Incyte (INCY) announced receiving the FDA node for its kinase inhibitor Pemazyre. The drug seeks to treat adults with previously handled, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. With this approval, Pemazyre has become the first and only treatment for the said indication. The drug was given accelerated approval on the basis of its overall response rate and duration of response. Further, continued approval will be based upon description